礼来公司首席财务官近日表示,其口服GLP-1受体激动剂Orforglipron在预期四月份获得监管批准后,最早可能在今年第二季度进入美国市场。这一时间表已得到投资银行TD Cowen的确认。
该药丸剂型若成功上市,将突破目前GLP-1类药物需注射给药的限制,为糖尿病和肥胖症患者提供更便捷的治疗选择。市场分析指出,口服制剂有望显著提升药物可及性,并可能进一步扩大礼来在代谢疾病治疗领域的市场优势。
礼来公司首席财务官近日表示,其口服GLP-1受体激动剂Orforglipron在预期四月份获得监管批准后,最早可能在今年第二季度进入美国市场。这一时间表已得到投资银行TD Cowen的确认。
该药丸剂型若成功上市,将突破目前GLP-1类药物需注射给药的限制,为糖尿病和肥胖症患者提供更便捷的治疗选择。市场分析指出,口服制剂有望显著提升药物可及性,并可能进一步扩大礼来在代谢疾病治疗领域的市场优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.